The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

Targeted Oncology

Volumn 8, Issue 3, 2013, Pages 203-209

  Al Marrawi, Mhd Y ^a   Rini, Brian I ^a   Harshman, Lauren C ^b,c   Bjarnason, Georg ^d   Wood, Lori ^e   Vaishampayan, Ulka ^f   MacKenzie, Mary ^g   Knox, Jennifer J ^h   Agarwal, Neeraj ⁱ   Al Harbi, Hulayel ^j   Kollmannsberger, Christian ^k   Tan, Min Han ^l,m   Rha, Sun Young ⁿ   Donskov, Frede N ^o   North, Scott ^p   Choueiri, Toni K ^b,c   Heng, Daniel Y ^j  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^f WAYNE STATE UNIVERSITY   (United States)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALGARY   (Canada)

^k BRITISH COLUMBIA CANCER AGENCY   (Canada)

^l DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^m INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

ⁿ Yonsei University College of Medicine   (South Korea)

^o AARHUS UNIVERSITY HOSPITAL   (Denmark)

^p UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

Association of TKIs; First line and second line VEGF inhibitors; Renal cell cancer; Tyrosine kinase inhibitors; VEGF targeted therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884279729     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0252-7     Document Type: Article

References (19)

1. Escudier B, Bellmunt J, Negrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144-2150
2. Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137-2143
3. Al-Marrawi MY, Rini BI (2011) Pazopanib for the treatment of renal cancer. Expert Opin Pharmacother 12(7):1171-1189
4. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061-1068
5. Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27(8):1280-1289, Erratum in J Clin Oncol. 2009 May 1; 27(13):2305
6. Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312-3318
7. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
8. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584-3590
9. Rini BI, Wilding G, Hudes G et al (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27(27):4462-4468
10. Rini BI, Wilding GT, Hudes G et al (2007) Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib [abstract]. J Clin Oncol 25(Suppl 1):Abstract 5032
11. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931-1939, Epub 2011 Nov 4
12. Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell cancer. J Clin Oncol 22(3):454-463
13. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372(9637):449-456, Epub 2008 Jul 22
14. Porta C, Paglino C, Imarisio I (2010) Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. Eur J Clin Med Oncol 2:1-6, 2010
15. Busch J, Seidel C, Kempkensteffen C et al (2011) Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 60(6):1163-1170
16. Heng DYC, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794-5799
17. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2010) Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 194(6):1470-1478
18. Krajewski KM, Guo M, Van den Abbeele AD et al (2011) Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 59(5):856-862
19. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256-4265